So what does Damien Hirst know about big pharma? On Baxter Labs based at Thousand Oaks, Tim Alefantis of Sanofi, COBRA, the NIH and biowarfare (pizzagatewhatever)

submitted ago by letsdothis2

Thousand Oaks is a very interesting place. For starters we have the Baxter Healthcare Corporation. They are so interesting Damien Hirst included them in his 'pharmaceutical' series : https://imgur.com/a/sTHMEti

[Thanks to @swordfish69 for pointing that out in this post: Massive Paul Manafort Bombshell Incoming: Manafort witnessed Clinton/Soros/AIDS NGO human trafficking and biowarfare operation in Ukraine while working for Yanukovych

Notice the one eye reference and check out the shoes ;-) There's also a reference to Abbott Laboratories reference in that image (brown box just above the second stool).

Well, Baxter, Dyncorp and the NIH worked together on the H1N1 virus : Tim Alefantis vaccine scientist and cousin of James A, the H1N1 virus, Bioport, and Dynport of Dyncorp. Why is the child trafficking industry and public health industry seemingly so closely connected?

It appears that DynPort (DVC), Baxter pharma and the National Institute of Health (NIH) may have colluded to create H1N1, develop a vaccine for H1N1 and ultimately profit from demand for the vaccine generated by the outbreak of the H1N1 swine flu.

[scientific paper here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297649/]

From this article : Stephen Hawking Says the Human Race is in Danger and it's our Own Fault

"Speaking to the Radio Times ahead of the BBC Reith Lecture, in which he will explain the science of black holes, Hawking said most of the threats humans now face come from advances in science and technology, such as nuclear weapons and genetically engineered viruses."

I found this comment in the article :

Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models. ....

The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus was similar to those found in pigs, but the virus now circulates as a seasonal form of influenza.

USING A TECHNIQUE CALLED COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGEN, OR COBRA, UGA RESEARCHERS DONALD CARTER, CHRISTOPHER DARBY AND BRADFORD LEFOLEY, ALONG WITH ROSS, CREATED NINE PROTOTYPE SYNTHETIC COMPOUND VACCINES CONSTRUCTED USING GENETIC SEQUENCES FROM MULTIPLE INFLUENZA VIRUS STRAINS.

and another comment from the same poster:

A while back, I researched the mycoplasma/weapon idea as thoroughly as the internet allows and came to the conclusion that a mycoplasma weapon has indeed been pursued. Just my opinion on that - no first hand knowledge at all. Linda, I think people aren't protesting because they aren't aware of the possibility that our government is looking at a mycoplasma weapon. When news sources talked about the mycoplasma/GWS connection, they always discussed the probability that those traumatized PTSD veterans were just looking for someone to blame, and maybe the news people might have insinuated that there could have been toxic exposures on the ground at the time, but, of course those can be guarded against in the future.

https://adamnews.net/2018/11/11/thousand-oaks-shooter-ian-long-marines-have-no-record-of-ptsd-issues/

Ian Long — the former Marine who killed 12 people in a country music bar allegedly suffered from severe PTSD, but there’s no record of him ever contacting the Corps for help … so says the military.

That's interesting, is it not?

You are viewing a single comment's thread.

view the rest of the comments →

letsdothis2 ago

Sanofi Pasteur Collaboration Uses Novel Technology towards Development of a 2nd Generation Influenza Vaccine

Previously, a novel hemagglutinin (HA) for H5N1 influenza was derived using a methodology termed computationally optimized broadly reactive antigen (COBRA). This COBRA HA elicited a broad antibody response against H5N1 isolates from different clades in mice and nonhuman primates. In this new publication, the authors present pre-clinical efficacy data demonstrating that COBRA technology can be extended to elicit antibodies against many drifted H1 strains and has the potential to be used in the development of a “subtype universal” vaccine. According to the authors, “One of the challenges of developing next generation influenza A vaccines is the diversity of antigenically distinct isolates. We now report the characterization of a COBRA-based vaccine for both seasonal and pandemic H1N1 influenza isolates.”

As described in the publication, nine HA COBRA candidates were designed and assessed as vaccines used alone, in cocktails, or in prime-boost combinations. The most effective regimens elicited the broadest hemagglutination-inhibition (HAI) response against a panel of H1N1 viruses isolated over the past 100 years – even against viruses whose sequences were not included in the design strategy. This study represents the first demonstration of a COBRA-based HA vaccine strategy that elicits a broadly-reactive response against both seasonal and pandemic H1N1 isolates.

Sanofi Pasteur has an existing R&D collaboration agreement with the University of Georgia to further design and develop novel synthetic vaccines based on the HA protein to help protect against disease caused by seasonal influenza strains spanning several years, including drifted strains not yet in existence. This would provide an advantage over traditional influenza vaccine manufacturing, which depends on the selection of candidate vaccine viruses by public health authorities following analysis of data collected through active surveillance of influenza viruses circulating each year.

“This experimental and novel vaccine is generated from the sequences of many flu viruses and is designed to help protect against many strains over several years,” explained Tim Alefantis, PhD, MBA, Sanofi Pasteur’s R&D lead on the 2nd generation vaccine program and one of the authors of the published findings. “The key advantage could be broader coverage against several seasonal flu strains.” He added, “An additional advantage of this approach is that it doesn’t rely upon annual strain selection, allowing year-round manufacturing.”

Posted today:

ELECTION THEFT IN GEORGIA? Panicked Dems and Shaun King losing their collective sh*t and make call out for lawyers on Twitter